Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | CXCR4 | P61073 | 2/20 | 0.41 |
| ▸ | RAD52 | P43351 | 1/20 | 0.40 |
| ▸ | SLC6A2 | P23975 | 12/20 | 0.39 |
| ▸ | SLC6A4 | P31645 | 5/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.37 |
| ▸ | SOS2 | Q07890 | 1/20 | 0.37 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4989467 | 0.98 | POLB (0.44) | POLBSMN1; SMN2CXCR4RAD52SLC6A2 | |
| SCHEMBL7088927 | 0.84 | HRH3 (0.42) | POLBSMN1; SMN2 | |
| SCHEMBL27097480 | 0.84 | HRH3 (0.42) | POLBSMN1; SMN2 | |
| SCHEMBL7091537 | 0.81 | HRH3 (0.39) | POLBSMN1; SMN2 | |
| SCHEMBL29889633 | 0.79 | HRH3 (0.42) | POLBSMN1; SMN2 | |
| SCHEMBL30472862 | 0.72 | RAD52 (0.40) | SMN1; SMN2CXCR4RAD52SLC6A2SLC6A4 | |
| SCHEMBL7625809 | 0.72 | CXCR4 (0.37) | POLBSMN1; SMN2CXCR4RAD52SLC6A2 | |
| SCHEMBL7091824 | 0.70 | HRH3 (0.30) | — | |
| SCHEMBL6913246 | 0.69 | CXCR4 (0.60) | POLBSMN1; SMN2CXCR4RAD52HSD17B10 | |
| SCHEMBL28078047 | 0.69 | CXCR4 (0.60) | POLBSMN1; SMN2CXCR4RAD52HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080227850-A1 | USE OF NOREPINEPHRINE REUPTAKE MODULATORS FOR PREVENTING AND TREATING VASOMOTOR SYMPTOMS | WYETH (US) | 2008-09-18 | — | — | US | disclosed |
| US-7345096-B2 | Use of norepinephrine reuptake modulators for preventing and treating vasomotor symptoms | WYETH (US) | 2008-03-18 | — | — | US | disclosed |
| US-6444677-B2 | TREATMENT OF INFLAMMATION, CARDIOVASCULAR DISEASE, PAIN, ETC. | PFIZER INC. | 2002-09-03 | — | — | US | disclosed |
| US-20010046993-A1 | 5-memberd heteroaryl substituted 1,4-dihydropyridine compounds as bradykinin antagonists | IKEDA TAKAFUMI (JP) | 2001-11-29 | — | — | US | disclosed |
| EP-1106614-A1 | 5-Membered heteroaryl substituted 1,4-dihydropyridine compounds as bradykinin antagonists | PFIZER INC. (US) | 2001-06-13 | — | — | EP | disclosed |
| US-5047406-A | Substituted cyclohexanols as central nervous system agents | WARNER-LAMBERT CO. (US) | 1991-09-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010046993-A1 | 5-memberd heteroaryl substituted 1,4-dihydropyridine compounds as bradykinin antagonists | BDKRB1, BDKRB2, CNR2 | POLB 4321/4885SMN1; SMN2 3038/4885CXCR4 112/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.